MVC’s WHO-Partnered Vaccine a First for Taiwan
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
In order to obtain genetic information for analysis and their applications for developing new drugs, precise and qualitative nucleic acid extraction steps are essential. This is Viogene’s primary focus. Viogene provides innovative and cutting-edge nucleic acids extraction technologies and products to allow scientists achieve their goals. Viogene currently has more than 40 nucleic acids extraction products for extracting nucleic acids from various biological sources such as animals, plants, microorganisms. Viogene sells its products in more than 30 countries worldwide.
Another part of Viogene’s research and development program is a platform of G protein coupled receptors (GPCRs) related drugs screening from traditional Chinese medicines (TCMs), GPCRs have proved to be very successful drug targets for more than 30% of marketed drugs which target directly or indirectly on GPCRs, which including the top 100 brand name prescription drugs, however mitigating side effects and increasing potency of GPCRs related drugs are marketed needed, Viogene’s GPCRs new drug screening and discovering programs from TCMs offer new solutions and opportunities for achieving the goals.
No.276, Ta-Tung Rd., Sec.1, Shijr,
New Taipei City, Taiwan
PHONE: 886 2 26472259
FAX: 886 2 26475094
Website: www.viogene.com
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
In an important milestone for Taiwan’s biotech industry, Diamond Biofund – one of the territory’s most well-established venture capital (VC) funds – became the first such firm to list on…
The latest pharma news from Taiwan, including Gongwin-KY’s lung cancer drug approval in China, Anxo Pharmaceutical/Genovior Biotech alliance, Taiwan’s Industrial Technology Research Institute (ITRI) and Metagone Biotech’s glaucoma and macular…
The latest healthcare and pharma news from Taiwan, including the CDMO Bora Pharmaceutical’s acquisition of Eden Biologics assets, the FDA fast track granted to the Taiwanese biomedical group United Biomedical’s…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have…
Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how it differs from sequencing technologies in terms of cost and speed,…
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have…
Taiwan Bio Industry Organization Chairman Dr Johnsee Lee outlines the Taiwanese biopharmaceutical industry’s rapid and coordinated response to the COVID-19 crisis and also explains how Quark Biosciences’ diagnostics and precision…
Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that is the envy of its neighbours. Here, three country managers for…
Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an enviable reputation at the forefront of some of the most innovative trends shaping global…
While Taiwanese pharmaceutical and biotech players have traditionally set their sights on the US as a key market, rising medical needs in Asia are helping foster more regionally-focused strategies. …
All country managers of multinational pharma companies need to strike the balance between having a global outlook and adapting to local culture. For BoonHuey Ee, general manager of Merck Biopharma…
See our Cookie Privacy Policy Here
